Investors should monitor upcoming clinical catalysts: BPL-003 Phase 3 initiation in Q2 2026, VLS-01 Phase 2 topline data in H2 2026, and BPL-003 Part 4 cohort data in Q4 2026. Despite strong cash runway and clinical progress, the massive non-cash loss may weigh on sentiment, though it does not reflect ongoing operating performance.
Price Chart
Executive Summary
AtaiBeckley Inc. reported its Q4 and full-year 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for BPL-003 in treatment-resistant depression, enabling Phase 3 initiation in Q2 2026. The company also announced positive Phase 2a results for EMP-01 in social anxiety disorder and extended its cash runway to early 2029 with $220.7 million in cash and short-term securities. However, net losses widened significantly due to a $530 million non-cash charge from the Beckley Psytech combination.
Key Financial Metrics
Key Facts
- FDA provided constructive feedback supporting Phase 3 initiation of BPL-003 for TRD in Q2 2026
- Phase 2a trial of EMP-01 in social anxiety disorder met primary safety endpoint and showed statistically significant efficacy (p=0.036)
- Cash, cash equivalents, and short-term securities totaled $220.7 million as of December 31, 2025, up from $72.3 million in 2024
- Net loss attributable to stockholders was $660.0 million for 2025 vs. $149.3 million in 2024, driven by $530 million in non-cash R&D acquisition expenses
- R&D expenses decreased slightly YoY to $53.1 million, while G&A expenses rose to $65.1 million due to combination-related costs
- Company expects cash runway into early 2029, covering key clinical readouts
Financial Impact
Significant non-cash charge of $530 million from in-process R&D related to Beckley Psytech combination; cash position increased by $148.4 million primarily from $291.1 million in equity proceeds
Risk Factors
- High cash burn rate: $102.7 million used in operations in 2025
- Clinical trial delays or failures in pivotal BPL-003 program could significantly impact valuation
- Equity dilution from $291.1 million in equity issuances may concern shareholders
- Reliance on successful integration and execution post-strategic combination
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250955 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 25-NSE | $7.30 awaiting T+20 | awaiting T+20 | — | — |
Aug 10, 2026 7w ago | DEFM14A | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Aug 9, 2026 7w ago | Institutional Cluster | $7.25 $7.28 | ▲ +0.41% | ▲ +1.33% | — |
Jul 16, 2026 11w ago | DEFA14A / 8-K | $7.15 $7.25 | ▲ +1.40% | ▼ −2.22% | — |
Jul 7, 2026 12w ago | 144 | $5.17 $7.22 | ▲ +39.65% | ▲ +36.38% | — |
Jul 6, 2026 12w ago | Press Release | $4.96 $7.18 | ▲ +44.76% | ▲ +45.32% | — |
Jun 26, 2026 14w ago | 144 | $5.36 $7.18 | ▲ +33.96% | ▲ +34.23% | — |
Jun 25, 2026 14w ago | 144 | $5.29 $7.17 | ▲ +35.54% | ▲ +34.28% | — |
Jun 3, 2026 17w ago | 8-K | $4.53 $5.19 | ▲ +14.57% | ▲ +15.57% | — |
May 12, 2026 20w ago | Press Release | $4.15 $3.78 | ▼ −8.92% | ▼ −7.19% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access